Billiontoone, Inc. (NASDAQ:BLLN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Billiontoone, Inc. (NASDAQ:BLLN) have earned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $138.6667.

BLLN has been the subject of several recent analyst reports. Jefferies Financial Group started coverage on shares of Billiontoone in a report on Monday. They set a “hold” rating and a $117.00 price objective for the company. Wall Street Zen upgraded Billiontoone to a “hold” rating in a research note on Saturday, November 15th. JPMorgan Chase & Co. began coverage on Billiontoone in a report on Monday. They issued an “overweight” rating and a $150.00 price objective for the company. Stifel Nicolaus began coverage on Billiontoone in a report on Monday. They set a “buy” rating and a $145.00 target price on the stock. Finally, BTIG Research assumed coverage on Billiontoone in a research report on Monday. They issued a “buy” rating and a $160.00 target price for the company.

Billiontoone Price Performance

Shares of NASDAQ:BLLN opened at $130.18 on Monday. Billiontoone has a 12-month low of $88.00 and a 12-month high of $138.70.

About Billiontoone

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.